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a  b  s  t  r  a  c  t
Seliciclib  (R-Roscovitine)  was  identiﬁed  as  an  inhibitor  of  CDKs  and  has  undergone  drug  development  and
clinical  testing  as an anticancer  agent.  In this  review,  the  authors  describe  the  discovery  of Seliciclib  and
give  a brief  summary  of the biology  of  the  CDKs  Seliciclib  inhibits.  An  overview  of  the  published  in vitro
and  in vivo work  supporting  the development  as an  anti-cancer  agent,  from  in vitro  experiments  to animaleywords:
eliciclib
ystems biology
DK
model  studies  ending  with  a summary  of  the  clinical  trial  results  and  trials  underway  is presented.  In
addition  some  potential  non-oncology  applications  are  explored  and  the  potential  mode  of  action  of
Seliciclib  in  these  areas  is  described.  Finally  the  authors  argue  that  optimisation  of the therapeutic  effects
of kinase  inhibitors  such  as  Seliciclib  could  be enhanced  using  a systems  biology  approach  involving
mathematical  modelling  of  the molecular  pathways  regulating  cell  growth  and  division.
Crown  Copyright  © 2015 Published  by Elsevier  B.V.  This  is an open  access  article  under  the  CC  BY
license (http://creativecommons.org/licenses/by/4.0/).. Introduction
The cell cycle is a fundamental biological process that is tightly
egulated by the activity of a series of kinases termed the Cyclin-
ependent Kinases (CDKs). These are such named because of the
equirement for binding CDK speciﬁc cyclins for their activity
Gran˜a and Reddy, 1995). The activities of these kinases must fol-
ow a speciﬁc sequence to allow normal cell cycle progression
Morgan, 1997) and abberations in the control of the cell cycle
ave been linked to a variety of diseases including cancer, inﬂam-
atory conditions and neurodegenerative disorders (Zhivotovsky
nd Orrenius, 2010). The cell cycle proceeds through various check-
oints each of which is regulated by the activity of CDKs that are in
urn, regulated by signalling pathways either promoting or inhibit-
ng cell (Chiarle et al., 2001).
The ﬁrst CDK to be discovered was CDK1, which was originally
dentiﬁed in starﬁsh oocytes as “Maturation Promoting Factor”
r MPF. It was found that when oocytes previously arrested in
he prophase of the cell cycle, were injected with CDK1, this
aused their entry into metaphase, a process known to be asso-
iated with protein phosphorylation (Meijer and Guerrier, 1984;
abbé et al., 1989). This observation, that the activity of CDK1, in
∗ Corresponding author. Tel.: +44 1382308536.
E-mail address: n.zhelev@abertay.ac.uk (N. Zhelev).
ttp://dx.doi.org/10.1016/j.jbiotec.2015.02.032
168-1656/Crown Copyright © 2015 Published by Elsevier B.V. This is an open access artcomplex with its partner Cyclin B (CDK1/cyclin B), was  required
for prophase to metaphase transition, suggested that inhibitors of
this kinase could be useful in the treatment of proliferative disor-
ders (Pondaven et al., 1990; Rialet and Meijer, 1991). Supporting
this hypothesis, Dimethylaminopurine (DMAP), a drug that was
initially identiﬁed as a potent inhibitor of mitosis in sea urchins
(Rebhun et al., 1973) was  subsequently shown to exert its action
through inhibition of CDK1/cyclin B complex (Rialet and Meijer,
1991; Neant and Guerrier, 1988). DMAP and a related purine
isopentyladenine had in vitro IC50 values of 120 M and 55 M
against CDK1/cyclin B respectively. The fact that isopentyadenine
was an intermediate in the biosynthesis of the cytokinin group
of plant hormones led to a collaboration between Laurent Mei-
jer of the Biological Station in Roscoff and Jaroslav Vesely and
Miroslav Strnad at the Institute of Experimental Botany in Olo-
mouc in the Czech Republic. Their collaborative work resulted
in the synthesis of a number of substituted purine molecules,
the most promising of which was  2-(2-hydroxyethylamino)-6-
benzylamino-9-methylpurine. This molecule, which was  named
Olomoucine, was  speciﬁc in its inhibitory action towards CDK and
MAPK (Vesely´ et al., 1994), an observation which, at the time,
was surprising for an ATP analogue. Olomoucine was consider-
ably more potent with an IC50 value of 7 M against CDK1/cyclin
B in vitro. Strnad in collaboration with Michel Legraverend of
the Institute Marie Curie at Orsay worked together to synthesise
more potent and more speciﬁc substituted purines, the best of
icle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
H.S. Khalil et al. / Journal of Biotec
Table  1
Studies demonstrating CDK inhibition by Roscovitine in vitro and in vivo.
CDK/Cyclin type Studied model Reference
CDK1 Lung cancer cell line Schutte et al. (1997)
CDK1 Human Colorectal cancer
cell line
Abal et al. (2004)
CDK1/Cyclin B Xenopus oocytes Meijer et al. (1997)
CDK1/Cyclin B In vitro kinase assay Meijer et al. (1997),
Raynaud et al. (2005)
CDK1/Cyclin B In vitro kinase assay Meijer et al. (1997),
Raynaud et al. (2005)
CDK1, CDK2 Human Gastric cell lines Iseki et al. (1997)
CDK2 Human Pancreatic cell line Iseki et al. (1998)
CDK2 Human Osteosarcoma,
Cervical, Lung carcinoma
cell lines
Zhang et al. (2004a,b)
CDK2/Cyclin A, E
& B
In vitro kinase assay Meijer et al. (1997),
Havlícek et al. (1997),
Biglione et al. (2007),
Raynaud et al. (2005)
CDK2/Cyclin B Mouse lymphocytic
leukaemia cell line
Meijer et al. (1997)
CDK2, Cyclin E In vitro kinase assay,
human tumour cell lines,
mouse model
McClue et al. (2002)
CDK2/Cyclin B HCT116 colon cancer cell
line
Raynaud et al. (2005)
CDK2/Cyclin D1,
Cyclin A2
Human breast cancer cell
lines
Nair et al. (2011)
CDK4/Cyclin D1 In vitro kinase assay Meijer et al. (1997),
Raynaud et al. (2005)
CDK4/Cyclin D1 HCT116 colon cancer cell
line
Raynaud et al. (2005)
CDK5/P35 In vitro kinase assay Meijer et al. (1997)
CDK6/Cyclin D3 In vitro kinase assay Meijer et al. (1997),
Raynaud et al. (2005)
CDK7/Cyclin H Invitro kinase assay Raynaud et al. (2005)
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Biglione et al. (2007),
Raynaud et al. (2005)
hich, 6-(benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-
-isopropylpurine, termed Roscovitine, had an in vitro IC50 value of
.45 M against the CDK1/cylin B complex (Havlícek et al., 1997).
oscovitine and olomoucine were subsequently co-crystallised
ith CDK2 and these structures were used as the basis of molecular
odels for guiding further medicinal chemistry programmes (De
zevedo et al., 1997).
Roscovitine has been demonstrated to be a potent inhibitor of a
umber of CDKs including CDK1/cyclin B (0.65 M), CDK2/cyclin A
0.7 M),  CDK2/cyclin E (0.7 M),  CDK5/p35 (0.2 M),  CDK7/cyclin
 (0.49 M),  and CDK9/cyclin H (0.79 M).  However, because
oscovitine is an ATP competitive molecule, the precise IC50 values
eported vary depending on the concentration of ATP used in the
n vitro assay (Wang and Fischer, 2008; Meijer et al., 1997; McClue
t al., 2002; Biglione et al., 2007). CDK4/cyclin D1, CDK6/cyclin D3
nd over 80 other kinases tested were all insensitive or only weakly
nhibited by Roscovitine (Bain et al., 2003, 2007).
As an inhibitor of CDKs 1, 2, 5, 7 and 9 Roscovitine can impact
 variety of cellular functions in tissue dependent manner. A sum-
ary of studies, demonstrating CDK inhibition by Roscovitine is
hown in Table 1. Thus, it is important to have knowledge of indi-
idual CDK functions especially while employing a broad spectrum
DK inhibitor. Here, we will brieﬂy examine the biology of different
DKs in an effort to ascertain which therapeutic areas inhibitors of
hese kinases could impact upon.
As an inhibitor of the CDK family roscovitine can potentially
mpact upon a number of fundamental processes in cellular biology.
ell division has to be highly regulated and is an area of cellular
iology in which the CDK family is heavily involved. Roscovitine-
arget CDKs 1 and 2 are involved in the control of the transition of
ells from G2 to M and G1 to S respectively and as the activity ofhnology 202 (2015) 40–49 41
these kinases is required for initiation and progression of cellular
division chemical inhibition of the CDKs has the potential to be
useful in proliferative diseases such as cancer.
2. CDK1
CDK1, also referred to as the mitotic kinase, forms a complex
with cyclin B (Malumbres and Barbacid, 2007) At 297 amino acids
in length and with a molecular weight of 34 kDa its activity is
modulated by post-translational modiﬁcation, being activated or
inhibited by site-speciﬁc phosphorylation by regulatory kinases
including Wee1, Mik1 amd  Myt1 on Threonine 161,Tyrosine 15 or
Threonine 14 (Schafer, 1998). Hyperactivity of CDK1 either through
overexpression of Cyclin B1 or hyperphosphoryation of CDK1 has
been observed, observed in several tumours, including breast-,
colon- and prostate carcinoma (Pérez de Castro et al., 2007) this
supporting the hypothesis that dysregulation of this kinases could
cause uncontrolled cellular division.
3. CDK2
Dysregulation of CDK2 activity has also been observed in a vari-
ety of malignancies further supporting the theory that inhibition
of the CDKs be Roscovitine could be beneﬁcial in the treatment
of proliferative diseases. Although CDK2 is a key cell cycle regula-
tor, critical for the transition into the S-phase of the cell cycle, mice
lacking the kinase are viable, suggesting that there are other kinases
which can compensate for any lack in CDK2 activity (Berthet et al.,
2003). CDK2 activity is controlled not just by phosphorylation
events by complexation with inhibitory protein partners such as
Cip/Kip and of course its cyclin partners Cyclin E and Cyclin A dys-
regulation of which has been observed in malignancies (Pérez de
Castro et al., 2007).
4. CDK5
CDK5 is required for central and peripheral nervous system
function (Cruz and Tsai, 2004) and has been implicated in numer-
ous neuronal functions including cytoarchitecture in the brain,
neuronal migration, synaptic plasticity, learning and memory and
may  be involved in the development of neurodegenerative disor-
ders including Alzheimer’s and Parkinson’s Diseases (Angelo et al.,
2006; Cruz and Tsai, 2004; Dhavan and Tsai, 2001). Treatment of
the lower eukaryote Dictyostelium discoideum with Roscovitine
led to an inhibition not only of the single-cell growth phase of the
organism but also arrested translocation of the protein between
the nucleus and cytoplasm raising the possibility that at least part
of the biological effects of Roscovitine may  be due to secondary
effects such as protein location (Huber and O’Day, 2012). Inhi-
bition of CDK5 in lower eukaryotes has also indicated a role for
the kinase in development, cytoskeletal organisation and calcium
channel function (Huber and O’Day, 2012; Prithviraj et al., 2012;
Wen  et al., 2013). CDK5 has also been implicated in modulating the
metastatic potential of breast and prostate carcinomas (Goodyear
and Sharma, 2007; Strock et al., 2006). It is unusual in that it
exhibits kinase activity only when bound to non-cyclin activators
CDK5R1 and CDK5R2 although structural studies on these proteins
have shown structural similarity with the cyclins (Cheung and Ip,
2012).
These observations that CDK5, a kinase that is inhibited by
Roscovitine broaden the therapeutic applications of the compound
further beyond the less well documented areas of proliferative dis-
ease and virology. The potential of Roscovitine to treat neurological
disorders such as Alzheimers and Parkinson’s is very exciting given
the paucity of treatments currently available for these treatments
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nd its low toxicity and excellent tolerability are surely plus points
n this therapeutic area.
. CDK7
CDK7 binds not only to its cyclin partner Cyclin H but also forms
 trimer with a third partner, MAT1. Termed the Cyclin-dependent
inase Activating Kinase or CAK this trimer phosphorylates CDKs 1,
, 4 and 6 on their key activating residues (Lolli and Johnson, 2005).
 role in cell division has been observed in some eukaryotic systems
ncluding yeast, where loss of activity causes cell cycle arrest and
rosophila in which mutations are lethal before or during pupation
Larochelle et al., 1998; Wallenfang and Seydoux, 2002). In mam-
alian cells loss of MAT1 induces cellular arrest in G1 and cell death
y apoptosis (Wu et al., 1999). The cell-cycle role of CDK7 in cell
eath is less clear cut than some of the other CDKs due to the fact
t is also involved in the control of transcriptional. CAK forms part
f the large multimeric general transcription factor TFIIH where it
hosphorylates the C-Terminal Domain (CTD) of RNA Polymerase
I improving the efﬁciency of transcriptional initiation and elonga-
ion (Maldonado and Reinberg, 1995). As the kinase has multiple
iological effects it is more difﬁcult to deﬁne unambiguously which
nhibition causes which effect.
. CDK9
CDK9 with its partner Cyclins T or K also forms part of the
ranscriptional machinery being a core part of the multi-subunit
ositive transcription elongation factor b (p-TEFb) (Loyer et al.,
005; Malumbres and Barbacid, 2005; Romano and Giordano,
008; Yu and Cortez, 2011) which is involved in improving the tran-
criptional elongation from RNA Pol II dependent promoters. This
lass of promoter drives expression of multiple key developmen-
al and cellular response genes as well as the majority of protein
ncoding genes (Nechaev and Adelman, 2011).
The discovery of role of the CDKs 7 and 9 in the control of gene
ranscription opened up new possibilities for roscovitine in new
herapeutic areas, most importantly in virology where the impor-
ance of their activity has been recognised in the replication of
erpes Simplex Virus, Human Imunodeﬁciency Virus and Human
ytomegalovirus (Boeing et al., 2010; Durand and Roizman, 2008;
chang et al., 1998; Yang et al., 1997)
. In vitro studies of Roscovitine as an anti cancer drug
Although CDKs play pivotal roles in a range of cellular functions,
tudies with Roscovitine have focussed largely on its inhibitory
ffects on cell cycle progression, mainly with a view to its develop-
ent as a potential anti-cancer agent. Roscovitine has been tested
n more than 100 cell lines, including the NCI-60 panel of the United
tates’ National Cancer Institute (Shoemaker, 2006).
In 1997, Meijer et al. showed that constant exposure to Roscovi-
ine over a 48 h period inhibited the growth of 60 different cell lines
rom 9 different tissue types when compared with non-exposed
ells. The average IC50 across all cell lines was 16 M (Meijer et al.,
997). In a separate study Raynaud and colleagues reported that
oscovitine inhibited the growth of 24 cell lines with an average
C50 value of 14.6 M (Raynaud et al., 2005). Other studies have
hown that in the mouse leukaemia cell line L1210, Roscovitine
ed to an accumulation of the cells in G2/M cycle. This accumula-
ion of cells in the G2/M phase was also observed in A549 human
ung cancer cell lines in a detailed study by McClue et al. (2002).
his group demonstrated that 24 h of treatment with Roscovitine
ed to a signiﬁcant increase in apoptosis. Schutte and colleagues
xamined the effects of both roscovitine and olomoucine on thehnology 202 (2015) 40–49
kinetics of the cell cycle in the human lung cancer cell line MR65
and the neuroblastoma line CHP212 (Schutte et al., 1997). In this
study, cells exposed to either of the compounds showed delays in
the transitions from G1 to S phase and from G2/M to G1 as well
as a prolonged S phase. They also observed changes in cell mor-
phology that were indicative of apoptosis in the treated cells. In
a study using normal human ﬁbroblasts, Alessi et al. reported a
reversible block in G1 after Roscovitine or Olomoucine treatments
(Alessi et al., 1998) and reduced levels of hyper-phosphorylated
Rb, indicating cell cycle arrest, but unchanged levels of Proliferat-
ing Cell Nuclear Antigen (PCNA) and Cyclins D1 and E. In another
study, treatment of human gastric cell lines SIIA, AGS, MKN45-
630 and SNU-1, resulted in an increase in the proportion of cells
in G2/M and S phases. In SIIA cells, treatment led to a reduction
in levels of phosphorylated Histone H1, suggesting that the com-
pound was inhibiting CDK1 and CDK2 (Iseki et al., 1997). A year
later, same group also examined four human pancreatic cell lines
with differing genetic lesions and showed that Roscovitine and
Olomoucine inhibited CDK2 activity and cellular proliferation inde-
pendent of the p53, K-Ras or p16 status (Iseki et al., 1998). During
the same year, Mgbonyebi and colleagues investigated the effect of
Roscovitine on the proliferation of immortal and neoplastic breast
cancer cells and reported that Oestrogen Receptor (ER) positive and
ER negative cell lines were sensitive to Roscovitine (Mgbonyebi
et al., 1998). In a further study, the same group reported that treat-
ment of ER-ve MD-MB-231 cells with Roscovitine for between
1 and 10 days induced morphological changes in the cells
consistent with the induction of apoptosis (Mgbonyebi et al.,
1999).
Responses to Roscovitine have also been investigated in com-
bination with a number of other chemotherapeutic agents in
vitro. It has been shown to have potential synergistic relationships
with camptothecin in the breast tumour line MCF7, the histone
deacetylase inhibitor LAQ824 in leukaemic cell lines HL60, with
doxorubicin in sarcoma cell lines and also with irinotecan in a p53-
mutated colon cancer (Lu et al., 2001; Lambert et al., 2008; Abal
et al., 2004).
We have previously studied the effects of R-Roscovitine
(CYC202) on the physiology of normal and transformed human
cells. These studies revealed for the ﬁrst time that at therapeutic
doses, the drug is not toxic to normal keratinocytes, but at higher
doses CYC202 can affect components of major signalling pathways,
(e.g. p38), highlighting potential side-effects of the drug in vivo
(Atanasova et al., 2005, 2007). In addition to the induction of apo-
ptosis and cell cycle effects, Roscovitine has been reported to inhibit
DNA synthesis in primary human glioma samples by almost 90%
(Yakisich et al., 1999) as well as inducing mucinous differentiation
in the human non-small cell lung cancer line NCI-H348 (Lee et al.,
1999).
In summary Roscovitine has been reported to induce apopto-
sis in several cell lines independently of p53 status. Cell death
has been detected in all phases of the cell cycle via a variety
of potential mechanisms including inhibition of the cell cycle
and effects on transcription due to reduced phosphorylation of
the CTD of RNA polymerase II by CDK7 and CDK9 (Wesierska-
Gadek et al., 2005, 2008). However, treatment with Roscovitine
had relatively little impact on global transcription with only a
small number of transcripts found to be signiﬁcantly reduced. It
is worth noting that those proteins whose transcript level was
found to be reduced by Roscovitine treatment were mostly pro-
survival factors on which tumour cells may  be more dependent
than normal cells (Meijer and Galons, 2006). These observations
suggest that cell death induced by Roscovitine may  be due to the
reduction in levels of a small number of survival factors such as
Mcl-1, XIAP and survivin (Lacrima et al., 2005; Mohapatra et al.,
2005).
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. In vivo studies of Roscovitine as an anti cancer drug
Roscovitine has been tested extensively in animal models,
argely in xenograft models of various cancers, as part of its devel-
pment as an anticancer agent. In addition it has been examined in
ll the standard toxicology tests required by regulatory authorities
nd although the authors are not aware of any toxicological issues,
hat data will not be discussed in this review.
In the xenograft models tested, Roscovitine has generally led
o reductions in tumour growth rather than absolute reductions in
umour volume. The compound has been dosed both by oral gav-
ge as well as by intra-peritoneal injection and a variety of dosing
chedules have been employed in the studies. In a report origi-
ally published in 2002, McClue et al. studied mice bearing tumours
erived from human uterine cell line MES-SA/Dx5 or the human
olon cell line LOVO, both cell lines being sensitive to Roscovitine
n in vitro studies (McClue et al., 2002). Mice with established LOVO
umours were treated with Roscovitine at a dose of 100 mg/kg by
ntra-peritoneal injection three times per day for 5 days. Tumour
olume was observed for 32 days following the initiation of treat-
ent, over which period Roscovitine treated mice showed 55%
f the tumour burden when compared to untreated control mice
McClue et al., 2002). Mice bearing MES-SA/Dx5 derived tumours
ere dosed intra-peritoneally three times per day either at a lower
ose of 200 mg/kg for 10 days or higher dose of 500 mg/kg for 3 days.
n both of the treatment regimes, tumour volumes were reduced
ompared to untreated control mice, to 65% of control at 200 mg/kg
nd to 38% of control in the mice treated at 500 mg/kg (McClue et al.,
002).
The most striking result with xenografts models using Roscov-
tine as a single agent was seen in mice bearing A4573 Ewings
arcoma derived tumours. In this study, mice dosed with Roscovi-
ine once per day by intra-peritoneal injection at a dose of 50 mg/kg
or 5 days showed an 85% reduction in tumour burden com-
ared to untreated mice at the end of the dosing period (Tirado
t al., 2005). Other studies have examined the effects of Roscov-
tine on mice bearing tumours of colon, lung, brain, breast and
asopharangeal origin. The effects of Roscovitine in these stud-
es have slowed tumour growth resulting in reductions in tumour
olume relative to control animals but has failed to cause reduc-
ions in absolute tumour volume (Cheng et al., 2012; Fleming
t al., 2008; Hui et al., 2009; Nair et al., 2011; Raynaud et al.,
005).
Consistent with in vitro studies, Roscovitine has also been tested
n combination with other anticancer agents or treatments in
n vivo studies. Most impressive was a combination of Roscovitine
ith ionising radiation for the treatment of mice bearing tumours
rom two Epstein–Barr Virus (EBV) positive cell lines derived from
asopharangeal cancer patients (Hui et al., 2009). In this study, mice
ere dosed with Roscovitine by intra-peritoneal injection twice per
ay for 5 days followed by a break for two days and then 5 further
ays of Roscovitine dosing. During dosing period, the mice were
reated twice with 6 Gy of ionising radiation. In a 30 day period
ollowing such treatments, treated mice developed only 20% of the
umour burden compared to untreated mice (Hui et al., 2009).
Fleming et al. examined the effects of a combination of Roscov-
tine and Erlotinib (a reversible Epidermal Growth Factor Receptor
EGFR) inhibitor) on tumour growth in mice bearing H358 non-
mall cell lung cancer tumours (Fleming et al., 2008). In a 28
ay treatment window, Erlotinib was dosed orally every day at
00 mg/kg and Roscovitine was dosed twice per day by intra-
eritoneal injection at 50 mg/kg on a 5 day on/2 day off schedule.
even weeks after the initiation of treatment, tumour volume in the
reated animals was just 7% of that in the untreated animals. In the
ame study Roscovitine alone showed no signiﬁcant reduction in
umour growth and Erlotinib alone reduced tumour growth by onlyhnology 202 (2015) 40–49 43
56% clearly showing that these two  compounds act synergistically
to reduce tumour growth (Fleming et al., 2008).
In another study, Roscovitine was  tested in a xenograft GBM43
glioma model in combination with an experimental PI-3 kinase
inhibitor, PIK-90 (Cheng et al., 2012). Both drugs were dosed intra-
peritoneally four times per day for 12 days, Roscovitine at 50 mg/kg
and PIK-90 at 40 mg/kg. At the end of the 12-day treatment period,
mice treated with the combination of the drugs showed 75% reduc-
tion in tumour volume as compared to that in untreated animals.
Treatment with Roscovitine or PIK-90 alone reduced tumour vol-
umes by approximately 40% and 50% respectively indicating that
the combination of the two  drugs was  not more than additive
(Cheng et al., 2012).
We  have identiﬁed the speciﬁc CDK inhibitor, p27 and its
substrate Rb, as biomarkers for CYC202 mediated cell growth inhi-
bition, and demonstrated its usefulness for monitoring inhibition
of its major target (CDK2) in cellulo and in vivo (Whittaker et al.,
2001; McClue et al., 2002; Zhang et al., 2004a).
In summary, the in vivo effects of Roscovitine as a single agent
for the treatment of xenograft models of cancer are mild. The great
advantage of the drug is that treatment is well tolerated making it
ideal for use in combination with other drugs or treatments where
tumour burden could be signiﬁcantly reduced while still remaining
well tolerated. Hence, it seems to the authors that the future of
Roscovitine in cancer will be its use in combination with other anti-
cancer agents.
9. Clinical studies using Roscovitine as an anticancer agent
Roscovitine (generic name Seliciclib) has been tested in a
number of Phase I and II clinical trials sponsored by the biopharma-
ceutical company Cyclacel Pharmaceuticals Inc. The drug has been
used to treat around 450 cancer patients and has shown a degree
of anticancer activity in around half of those patients. In an initial
Phase I trial with patients suffering from refractory solid tumours, a
schedule of oral dosing of twice per day for 7 days in a 21-day cycle
was used. A maximum tolerated dose of 800 mg  with dose limit-
ing toxicities of fatigue, rash, hyponatremia and hypercalcemia was
reached. Although no tumour reductions were observed, stable dis-
ease was  recorded in 8 patients (Benson et al., 2007). A subsequent
Phase I trial in cancer patients was  carried out using different dos-
ing schedule and reached a maximum tolerated dose of 1800 mg
twice per day when dosing twice daily for 3 days in a 2 week
cycle. One hepatocellular cancer patient had a partial response to
treatment and others had periods of stable disease. Dose limit-
ing toxicities were similar to those observed in the initial trial (Le
Tourneau et al., 2010). Roscovitine has also been tested in a Phase
I trial in combination with Gemcitabine and Cisplatin in non-small
cell lung cancer patients. The maximum tolerated dose of Roscov-
itine was  800 mg  in combination with 1000 mg/m2 Gemcitabine
and 75 mg/m2 Cisplatin. Interestingly, for this drug combination
the level of haematological toxicity observed was  relatively low
(Siegel-Lakhai et al., 2005).
Interim results from a Phase I trial of patients with nasopha-
rangeal and other solid tumours, 7 of the 10 patients with
nasopharangeal tumours and 4 of the 13 patients with other solid
tumours had stable disease while on trial. Dosing in this trial was
orally administered at either 400 mg  or 800 mg  of Roscovitine for
4 days in a 2-week cycle. Both dosing regimens were considered
tolerable with results being positive enough to warrant further
investigation in a randomised trial of patients with nasopharangeal
cancer (NPC) (Yeo et al., 2009). Another NPC study reported that half
of the evaluable patients showed signs of a reduction in tumour
volume and tumour biopsies from before and after treatment
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uggesting that Roscovitine was inducing apoptosis and necrosis
n the tumours (Hsieh et al., 2009).
Roscovitine has been evaluated in a Phase II trial in 187 patients
uffering with Non-Small Cell Lung Cancer (NSCLC). The trial
ailed to meet the primary endpoint of improving progression
ree survival but patients treated with the drug did show longer
edian survival (Cyclacel, 2010). Roscovitine is also undergoing
linical testing as a combination treatment together with nucle-
side analogue Sapacitabine (CYC682) in patients with advanced
olid tumours (Cyclacel, 2013a), as well as in combination with
GFR inhibitor Erlotininb (Tarceva) in patients with advanced solid
umours markers (Cyclacel, 2008) and ﬁnally in the treatment of
atients with rheumatoid arthritis, who have not responded to
urrent conventional treatments (Cyclacel, 2013b).
0. Beyond cancer; potential of Roscovitine as a
herapeutic drug for other diseases
0.1. Kidney disease
Polycystic kidney disease (PKD) is one of the most common life-
hreatening genetic diseases affecting some 12.5 million people
cross the globe (Anon, 2014). The condition is normally inherited
n a dominant Mendelian manner, but can also be passed on reces-
ively, and causes the formation of multiple, ﬂuid-ﬁlled cysts in
he kidneys. This leads to massive enlargement of kidneys and in
unction (Martinez and Grantham, 1995). Mutations in PKD genes
re thought to disrupt localisation of ion channels and growth fac-
or receptors and lead to ﬂuid retention and cellular proliferation in
he kidney. This increased renal cell proliferation has been targeted
sing roscovitine, an approach that has met  with some success in
ouse models of both indolent (jck) and aggressive (cpk) forms
f the disease (Bukanov et al., 2006). Treatment with Roscovitine
nhibited disease progression and improved renal function. Renal
ells from treated mice showed reduced levels of phosphorylation
n both Rb and Cyclin D, observations consistent with a block at
he G1/S phase of the cell cycle (Bukanov et al., 2006). Roscovitine
as been examined in a number of animal models of various vari-
ties of Glomerulonephritis and has been shown to help prevent
r improve pre-existing disease and demonstrated reductions in
nﬂammatory markers associated with the disease (Milovanceva-
opovska et al., 2005; Pippin et al., 1997; Sheryanna et al., 2011;
oja et al., 2007).
0.2. Potential of Roscovitine to combat viral infections
The use of Roscovitine to combat viral infections is based on the
ationale that viruses, such as papilloma- or adeno-virus, can repli-
ate only in dividing cells and hence show a requirement for cellular
DK activity to drive the cell into and through the phase of the cell
ycle. As such, inhibition of host cell’s CDK activity may  cause cessa-
ion of viral replication. Viruses, such as Human Immunodeﬁciency
irus (HIV) and Herpes Simplex Virus (HSV), which can replicate in
on-dividing cells, have a less obvious requirement for CDK activity,
lthough some studies have revealed that, at least in vitro, replica-
ion of many of these viruses can be inhibited roscovitine. Human
ytomegalovirus (HCMV) infection in healthy individuals is rare
espite exposure being common. However in immune compro-
ised patients, infection with HCMV is a signiﬁcant issue and leads
o increased levels of morbidity and mortality. Infection acts on cells
nd create an environment favourable to viral replication that can
e disrupted by small molecule ATP mimics such as Roscovitine.
n one such study, treatment of HCMV infected cells with Roscovi-
ine reduced viral replication possibly by reducing phosphorylation
f the key viral regulatory protein pUL69 by CDK9/cyclin T1 andhnology 202 (2015) 40–49
disruption of its localisation (Rechter et al., 2009; Sanchez et al.,
2003; Schang et al., 2006).
Efﬁcient Human Immunodeﬁciency Virus-1 (HIV -1) gene
expression relies on RNA Pol II CTD phosphorylating activity of
CDK7 (Boeing et al., 2010) and CDK9 (Yang et al., 1997). Further-
more, cells latently infected with HIV-1 lose the proteinaceous
CDK inhibitor p21/waf1 leading to increased CDK2/cyclin E activ-
ity (Clark et al., 2000). These ﬁndings clearly provided a rationale
for employing Roscovitine based therapies, which could theoreti-
cally have the potential to be an effective anti-HIV-1 agent. Indeed,
In vitro Roscovitine treatment demonstrated reduction in viral titre
of both wild-type and drug resistant strains of HIV-1 and with an
induction in apoptosis in T-cells, monocytes and PBMCs irrespec-
tive of the phase of the cell cycle (Agbottah et al., 2005).
Although Herpes Simplex Viruses (HSVs) encode protein kinases
within their genome, many still rely on host cell kinase activity for
successful replication. Consistent with this CDK9 has been reported
to enhance viral transcription by phosphorylating the CTD of RNA
Pol II (Durand and Roizman, 2008). Roscovitine and Olomoucine
have been shown to inhibit HSV replication via a non-cell cycle
blocking mechanism (Schang et al., 1998, 1999).
10.3. Roscovitine as an anti-inﬂammatory drug
Roscovitine has recently been explored for its potential as an
anti inﬂammatory agent. This is due to the observation that CDK
inhibitors such as Roscovitine can induce neutrophil apoptosis as
well as block lymphocyte proliferation (Leitch et al., 2009). Rossi
et al. examined the effects of Roscovitine in a mouse carrageenan-
induced pleurisy model and a mouse bleomycin-induced lung
injury model. Their results showed that Roscovitine caused a reduc-
tion in oedema, levels of inﬂammatory markers and increased
survival of treated mice relative to controls (Rossi et al., 2006).
Furthermore, Leitch and colleagues have shown that the anti-
inﬂammatory action of Roscovitine in neutrophils is due to a
reduction in RNA Pol II transcription and induction of apoptosis
caused by inhibition of CDKs 7 and 9 (Leitch et al., 2012).
Pneumonia is a lung disease that kills about 4 million peo-
ple per year worldwide and is typically caused by bacterial or
viral infection. Streptococcus pneumonia is a common causative
agent whose cell wall contains the pro-inﬂammatory molecule
lipoteichoic acid (LTA). This chemical induces release of reac-
tive oxygen, hydrolases, proteases, growth factors and cytotoxic
cytokines from macrophages and neutrophils. It has been found
that treatment of alveolar macrophages and respiratory epithe-
lial cell lines with Roscovitine following exposure to LTA led to a
reduction in the secretion of TNF- and keratinocyte chemoattrac-
tant (KC) (Hoogendijk et al., 2012). In the same study it was also
shown that Roscovitine reduced the number of Polymorphonuclear
leukocytes in the lungs of mice with LTS-induced inﬂammation
(Hoogendijk et al., 2012).
10.4. Roscovitine in the prevention of ischaemia/stroke induced
tissue damage
Ischaemic strokes cause tissue damage and loss of function to
parts of the brain when blood ﬂow to these areas is reduced. S-
Roscovitine has been tested in models of ischaemia and was shown
to cross the blood:brain barrier. Furthermore, it caused a reduction
in CDK5/p25 activity and reduced brain damage when dosed after
an experimentally induced ischaemic episode (Menn et al., 2010).
During transplant or bypass surgery, stroke or myocardial
infarction tissue is starved of blood ﬂow, and hence oxygen, before
ﬂow is returned. This transient ischaemia can induce inﬂamma-
tion and oxidative stress and cause damage to the organ when
blood ﬂow is reinstated (Clavien et al., 1992; Langdale et al., 1993).
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n response to previously reported anti-inﬂammatory effects of
oscovitine, Aydemir and colleagues tested it in a rat model of
enal ischaemia/reperfusion (IR). Upon treatment with Roscovitine,
ollowed by assessment of circulating biomarkers and histopatho-
ogical examination, the authors concluded that there was  less renal
amage in the disease model as compared to the untreated coun-
erparts (Aydemir et al., 2002). Topaloglu et al. also concluded that
re-treatment with Roscovitine reduced the number of dead cells,
poptotic cells and leucocyte inﬁltration in the livers of rats that had
nduced-IR to the right hepatic lobe, consistent with a protective
ffect and reduced inﬂammation (Topaloglu et al., 2003).
0.5. Roscovitine in anti ﬁbrotic therapy
Scleroderma is a condition in which excess connective tissue
s formed either cutaneously or systemically leading to changes
n the vasculature. Roscovitine has been shown by Steinman and
olleagues to reduce expression of collagen, ﬁbronectin and con-
ective tissue growth factor (CTGF) in systemic sclerosis ﬁbroblasts.
his was owing to the ability of Roscovitine to cause a reduction
n transcription of the genes, an effect that could not be reversed
y treatment with pro-ﬁbrotic cytokines (Steinman et al., 2012).
iven the lack of current therapies for Scleroderma, these obser-
ations certainly support further investigation and advocate the
mportance of Roscovitine as a therapy option for ﬁbrosis
0.6. Roscovitine in glaucoma
Glaucoma is a term used to describe a number of eye disor-
ers caused by changes in intraocular pressure, most commonly
ssociated with increased intraocular pressure. If left untreated,
laucoma can lead to irreversible retinal damage and blindness.
oth R- and S-Roscovitine have been evaluated in a rabbit glau-
oma model and have been shown to reduce intra-ocular pressure
Kasai et al., 2013).
0.7. Roscovitine in controlling seizures
Paroxysmal attacks are short seizures that are associated with
ther disorders including multiple sclerosis, head injury, stroke and
pilepsy amongst others (Anon, 2007). Gamma  Amino Butyric Acid
GABA) is a mammalian neurotransmitter and plays a key role in
he control of neuron excitability by binding and altering activity of
ts GABA receptor. Small molecules, such as Roscovitine, have also
een shown to alter GABA receptor activity and thus represent an
venue that could be of potential beneﬁt in the treatment of neu-
ological conditions such as epilepsy. Ivanov et al. have shown that
oscovitine increases GABA mediated current in rat hippocampal
eurons without modifying GABAA receptors and suppresses “spik-
ng” in hippocampal pyramidal cells. This activity may  ultimately
e of beneﬁt in the treatment of paroxysmal activity and is certainly
orthy of further research (Ivanov et al., 2008).
0.8. Roscovitine in the treatment of neurodegenerative diseases
Given the association of aberrant CDK5 activity with neurologi-
al conditions such as Alzheimer’s, Parkinson’s, Niemann Pick Type
 (NPC) and Amyotrophic Lateral Sclerosis (ALS). roscovitine has
een tested in some disease-relevant animal models (Kusakawa
t al., 2000; Hung et al., 2005; Lopes et al., 2007).
Zhang et al. have demonstrated that roscovitine decreased phos-
horylation of tau and other neuroﬁlament and mitotic proteins
hen dosed via the intracerebroventricular route in a mouse model
f Niemann-Pick Type C disease. Importantly this effect on mark-
rs of CDK5 activity was accompanied by an improvement in motorhnology 202 (2015) 40–49 45
defects typical in the condition and also had effects on Purkinje neu-
ron lifespan and the formation of axonal spheroids (Zhang et al.,
2004b).
In a rat model of Parkinson’s Disease (PD) Chagniel and col-
leagues investigated the effect of roscovitine and calpain inhibitors
on abnormal involuntary movements (AIMS) associated with the
condition. Intrastriatal infusion of roscovitine reduced the severity
and amplitude of AIMS as well as reversing biomarkers associated
with L-DOPA-induced dyskinesia (LID). The effect on the symptoms
of PD by CDK5 inhibition by roscovitine was less marked than for
the calpain inhibitor suggesting that inhibition in the formation of
CDK5/p25 is more effective than inhibiting the aberrantly activated
kinase itself (Chagniel et al., 2012).
Despite the evidence that CDK5 activity is implicated in the aeti-
ology of Alzheimer’s disease Sadleir and Vassar have reported that
treatment of primary neurons with roscovitine could cause eleva-
tion of the -secretase enzyme BACE-1 that initiates the formation
of amyloid- peptide that comprises amyloid plaques in the brains
of sufferers, a potentially negative effect (Sadleir and Vassar, 2012).
10.9. Roscovitine treatment in preventing cardiac hypertrophy
Cardiac hypertrophy may  represent a physiological or patho-
logical condition in which cardiac myocytes expand in size giving
rise to a hypertrophic heart. While the onset of heart hypertrophy
may  represent heart’s physiological requirement in order to meet
the blood pumping overload, persistent hypertrophic condition
may  cause detrimental effects on tissue and permanent damage
(Krystof et al., 2010). The principle behind employing a Roscovitine-
based therapy to prevent hypertrophy is that hypertrophic cells
show elevated levels of transcription and translation demonstrat-
ing hyperactive CDK’s, especially CDK9 that is involved in activation
of RNA pol-II (Trifonov et al., 2013). To investigate drug effects
on cardiovascular physiology, we  ﬁrstly developed a ‘mini-hearts’
assay, consisting of organ cultures of human stem cell-derived car-
diomyocytes. Using the organ culture model, our studies showed no
evidence of any treatment-related effects on cardiomyocyte physi-
ology. We  then induced hypertrophic condition in our organ culture
and ﬁnally demonstrated that R-Roscovitine (CYC-202) was  able to
prevent development of heart hypertrophy in vitro in vitro (Zhelev
et al., 2013a,b).
The above examples serve to demonstrate the promise of small
molecule inhibitors, such as Roscovitine, in combating variety of
disease phenotypes owing to the multifaceted roles of their tar-
gets; CDKs. However, the same also presents a challenge because of
the general involvement of CDK function in numerous essential bio-
chemical pathways. This not only mandates achieving speciﬁcity in
action of the drug towards its target itself, but also in inhibition of
its target in context dependent manner. This might warrant devis-
ing treatment regimes selective for their action in either speciﬁc
tissue types, in cell cycle dependent manner or in threshold depen-
dent manner (e.g. only inhibiting CDK with activity beyond a certain
threshold). We believe that owing to the ubiquitous nature of CDK
function, and the associated alteration of the complex biochemi-
cal signalling cascades resulting from their inhibition, a systematic
approach is required that study pathway components globally. This
warrants a Systems Biology approach for pathway analysis (next
section).
11. Role of systems biology in drug discovery and
developmentOver the last quarter of a century new techniques have
allowed biological scientists to capture increasing quantities of
data. Initially high-throughput screening (HTS) allowed scientists
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o automate the testing of libraries of hundreds of thousands
f different molecules allowing the identiﬁcation of molecules
hat modulated very speciﬁc biological processes. In parallel the
evelopment of microarray technology quickly allowed biological
cientists to measure the effect of a stimulus on the expression of
ll 30,000 plus genes in a cell simultaneously. More recently devel-
pments in next generation sequencing (NGS), proteomics and
etabolomics have allowed scientists to rapidly sequence all 3 bil-
ion base pairs of the human genome and identify post-translational
hanges in proteins and in the levels of cellular metabolites on a
cale that was unimaginable just a generation ago.
The massive increase in data available has increased the pres-
ure to devise novel methods of interpreting the massive quantities
f data now available. The new techniques have developed meth-
ds in isolation for analysing the data produced, for example in HTS
obust methods now exist for the identiﬁcation of the molecules
hich modulate a biological process and likewise with microarray
xperimentation, data analysis is robust in identifying the tran-
cripts whose expression has been altered by a biological stimulus.
he great challenge for the next generation of data scientists is to
evise methods to analyse and cross-reference all the data from
ll the newly developed technologies and to allow its use in a
ruly integrated manner (Clyde et al., 2011). The biological sciences
ndustry and allied industries such as the pharmaceutical have
riven the development of these technologies and have invested
illions of dollars to date but still the fruit of these labours are still
o be seen in the development of new drugs which according to
DA statistics have declined over the period in which these new
echnologies have appeared (FDA, 2013)
Systems biology is a powerful tool and its utilisation in drug
iscovery and design is an exciting and encouraging development
Clyde et al., 2006). The intrinsic properties and features of a sys-
ems biology approach make it particularly suitable for integration
nto the process of drug discovery and design. Firstly, by deﬁnition,
ystems biology is the quantitative characterisation of complex
nterrelationships of biological systems and how they communi-
ate and interact to bring about a biological change. Following the
nitial steps of qualitative characterisation, the process of drug dis-
overy requires establishment of multiple quantitative parameters,
.g. half life of drug, drug dose and time dependency, degree of inhi-
ition and potency, all of which require quantitative analyses that
orm the basis of the systems biology approach. Secondly, char-
cterisation of off-target effects of drugs is a central criterion on
hich drug effectiveness and efﬁcacy is founded. System biology
nvolves the analysis of the whole biological network of a given
rocess. A key feature of dynamic modelling of biochemical path-
ays through systems biology is sensitivity analysis. This not only
etermines and underpins key nodes in the network of signalling
hich are critical to form the functional module, but also links that
verall functional module with individual components of network
Lebedeva et al., 2012; Idowu et al., 2011). Such information could
e vital for drug discovery process for the characterisation of off
arget effects and the overall effect on physiology at the cellular
nd the whole organism level. Third is the growing realisation of
he requirement for a holistic approach to drug discovery and for
dentifying druggable targets. This is due to the fact that the reduc-
ionist approach deﬁned earlier for simpler systems (one protein,
ne function), does not take into account a fundamental prop-
rty of biological systems, manifested as emergent behaviour. This
mergent behaviour could only be accounted for through systems
iology approach, which parameterises a particular biological pro-
ess as a whole. This feature makes systems biology a vital tool for
rug development and target validation. Furthermore, drugs based
n simple, reductionist models limit the scope and space for wider
arget identiﬁcation and unexpected effects, which using the global
pproach intrinsic to systems biology could be avoided. The fourthhnology 202 (2015) 40–49
aspect is related to economic and social implications. Using molec-
ular modelling approaches, the early in silico determination of the
properties of novel drugs could eliminate some aspects of biolog-
ical testing. Robust predictive in silico modelling, based on many
chemical structures, of half life and drug retention times, would
be cheaper and could avoid or reduce animal and perhaps human
testing.
As mentioned above, technological advancements and high
throughput technologies have shifted the bottleneck from data
generation to data interpretation. Mathematical modelling of
complex biological systems and systems biology has previously
exposed features of signalling not obvious from biological analysis
alone (Idowu et al., 2013). This will be instrumental in delivering
the beneﬁts of employing systems biology in the drug discovery
domain as scientists realise that the primary drug targets could be
quite remote from the immediate signalling network implicated in
a disease phenotype. Moreover, unless a drug candidate is abso-
lutely speciﬁc, some degree of predictive power will be provided
only if a systems biology approach is utilised.
An integrated approach for drug discovery via systems analy-
sis could allow for the deciphering of complex biological networks
and generating novel hypotheses. These hypotheses could present
themselves as new avenues of intervention within a network of
signalling complex for lead compound development.
The development of systems protocols is a stepwise process
and should allow for directed evolution. A prerequisite for initial
development is not just large amount of relevant quantitative data
(e.g. the -omics approach), but best approximations of contextual
information of the disease, e.g. Cancer microenvironment, disease
history and therapy history etc. Ideally, such information should
be derived from tissues for which data from non-diseased tissue
also exists. The initial steps will involve bioinformatics and sta-
tistical analyses to establish correlations and propose cause and
affect relationships. Statistical protocols will then need to be devel-
oped based on which, after ﬁltering information for relevance such
as biological context and experimental setting, a priori disease
knowledge be must incorporated. A framework and network tem-
plate of the topology of the disease could then be developed via
computer simulation with the input of biological insights from
experts operating within relevant biological domains. Each node
in the network would represent a quantiﬁable biological variable,
e.g. up- or down-regulation of expression, differential localisa-
tion, post-translational modiﬁcation, protein–protein interaction,
degradation and so on, and inter-relationships between different
nodes could be developed making use of temporal data and novel
information from biological experimentation. At this point, the
model may  suggest development of novel cell based assays that
provide data on a particular signalling aspect that could indepen-
dently conﬁrm and validate some of the assumptions of the model
(Tummala et al., 2012). Different functional modules could then
be identiﬁed within the wider network and connections between
individual modules established.
Once such a framework is developed, it could be used for sensi-
tivity analysis for each node, accelerate hypothesis generation and
computationally ﬁne-tune the functional modules for exploratory
purposes and to achieve speciﬁcity towards diseased phenotypes
and comparison with the normal phenotype. The predictive net-
work simulation model could then propose speciﬁc intervention
strategies and short list possible druggable targets in the whole
network. In silico manipulation of different functional centres
within the network could be performed and the resulting sig-
nalling responses and compensatory pathways that could either
resist or accentuate any responses to intervention could be iden-
tiﬁed and examined. This would be particularly useful as many
growth signalling pathways may  respond unexpectedly to novel
drugs (Goltsov et al., 2014a,b) A global systems analysis, one that
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s developed through systems biology, may  highlight any such
ompensatory cancer speciﬁc pathways that emerge and suggest
lternative or multiple drug targets (Goltsov et al., 2014a,b). Such
ystems biology protocols for drug development could not just aid
n drug target identiﬁcation, but also devise and inform treatment
egimes, e.g. monotherapy vs. combination therapy, or simultane-
us vs. sequential combination therapy or full inhibition vs. partial
nhibition etc. (Khalil et al., 2012; Tummala et al., 2012; Zhelev
t al., 2014).
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